The Role of SN‐38 Exposure, <i>UGT1A1*28</i> Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan ToxicityRoshni Ramchandani, Jogarao Gobburu, Yaning Wang et al.|The Journal of Clinical Pharmacology|2006Cited by 84
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Richard Pazdur, Julia A. Beaver et al.|Clinical Cancer Research|2016Cited by 80
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Richard Pazdur, Michael H. Brave et al.|Clinical Cancer Research|2016Cited by 54
Proceedings of a Workshop: Precision Dosing: Defining the Need and Approaches to Deliver Individualized Drug Dosing in the Real‐World SettingKimberly Maxfield, Issam Zineh, Bernadette E. Johnson‐Williams et al.|Clinical Pharmacology & Therapeutics|2020Cited by 23
Creatinine‐Based Renal Function Assessment in Pediatric Drug Development: An Analysis Using Clinical Data for Renally Eliminated DrugsYifei Zhang, Jian Wang, Catherine M.T. Sherwin et al.|Clinical Pharmacology & Therapeutics|2020Cited by 17